DIMERIX LIMITED

INVESTOR PRESENTATION - DIMERIX LIMITED

ASX:DXB

DIMERIX LIMITED

Health Care

Dimerix is a clinical stage drug development company. The Company’s lead drug candidate DMX-200 is a chemokine receptor blocker. The Company’s clinical plan involves combining DMX-200 with Irbesartan, a angiotensin receptor blocker indicated for the treatment of hypertension and nephropathy in patients with kidney disease. DMX-200 is currently being tested in two Phase II clinical trials. Both trials are fully recruited and are due to report results in Q2 2020. The first study is targetting the rare chronic kidney disease FSGS and the second is targetting diabetic kidney disease. DMX-200 was discovered using the Company’s proprietary Receptor-HIT assay. Recently the Company announced that it had discovered its next pipeline candidate using the assay, DMX-700. DMX-700 will be investigated for the use in treating Chronic Obstructive Pulmonary Disease.

Read more

Market Cap

113.71m

Price at Close

$0.575

4w avg. Volume

1.34m

4w avg. Turnover

$613.40k

Announcements
announcementt+2 movementdate
  • Investor Presentation

    Periodic Reports

  • +23.68%

    28 Jul 2020

+23.68%

28 Jul 2020
  • Positive Top-Line Results in FSGS Phase 2a Clinical Study

    Stock Exchange Announcement · Market sensitive

  • +23.68%

    28 Jul 2020

+23.68%

28 Jul 2020
  • Trading Halt

    Stock Exchange Announcement · Market sensitive

  • +19.74%

    26 Jul 2020

+19.74%

26 Jul 2020
  • Last Patient Completes Dosing in DKD Phase 2 Clinical Study

    Progress Report · Market sensitive

  • 0.00%

    23 Jul 2020

0.00%

23 Jul 2020
  • Change in substantial holding

    Shareholder Details

  • +2.94%

    19 Jul 2020

+2.94%

19 Jul 2020
  • Quarterly Appendix 4C and Activities Report

    Commitments test entity quarterly reports · Market sensitive

  • -8.22%

    13 Jul 2020

-8.22%

13 Jul 2020
  • DMX-700 Program for COPD Advances

    Progress Report

  • -9.33%

    05 Jul 2020

-9.33%

05 Jul 2020
  • Cleansing Notice

    Issued Capital

  • +7.14%

    28 Jun 2020

+7.14%

28 Jun 2020
  • Appendix 2A

    Issued Capital

  • +7.14%

    28 Jun 2020

+7.14%

28 Jun 2020
  • Proposed issue of Securities - DXB

    Issued Capital

  • -1.30%

    21 Jun 2020

-1.30%

21 Jun 2020
Market Data

Current Price

$0.575

52WK HIGH

$0.595

52WK LOW

$0.087

1YR RETURN

+480.81%

1YR RETURN VS. SECTOR

+444.70%

90 DAY RETURN

+116.98%

ASX RANK

697

/2,032

SECTOR RANK

12

/47

SHARES OUTSTANDING

197.75m
ASX:DXB

DIMERIX LIMITED

Health Care

Dimerix is a clinical stage drug development company. The Company’s lead drug candidate DMX-200 is a chemokine receptor blocker. The Company’s clinical plan involves combining DMX-200 with Irbesartan, a angiotensin receptor blocker indicated for the treatment of hypertension and nephropathy in patients with kidney disease. DMX-200 is currently being tested in two Phase II clinical trials. Both trials are fully recruited and are due to report results in Q2 2020. The first study is targetting the rare chronic kidney disease FSGS and the second is targetting diabetic kidney disease. DMX-200 was discovered using the Company’s proprietary Receptor-HIT assay. Recently the Company announced that it had discovered its next pipeline candidate using the assay, DMX-700. DMX-700 will be investigated for the use in treating Chronic Obstructive Pulmonary Disease.

Read more

Market Cap

113.71m

Price at Close

$0.575

4w avg. Volume

1.34m

4w avg. Turnover

$613.40k

ASX:DXB is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Support

Ask Fresh

Archive
Contact Us

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

(03) 9028 2888

deals@freshequities.com

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.